Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

BACKGROUND: Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ER-positive BCs do not respond to those therapies. Aside from genomic signaling, estrogen triggers non-genomic pathways by forming a complex containing methyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacquemetton, Julien, Kassem, Loay, Poulard, Coralie, Dahmani, Ahmed, De Plater, Ludmilla, Montaudon, Elodie, Sourd, Laura, Morisset, Ludivine, El Botty, Rania, Chateau-Joubert, Sophie, Vacher, Sophie, Biche, Ivan, Treilleux, Isabelle, Trdan, Olivier, Marangoni, Elisabetta, Le Romancer, Muriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139055/
https://www.ncbi.nlm.nih.gov/pubmed/34020697
http://dx.doi.org/10.1186/s13058-021-01433-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139055/
https://www.ncbi.nlm.nih.gov/pubmed/34020697
http://dx.doi.org/10.1186/s13058-021-01433-8

Ejemplares similares